Alpha 2.0
Login Register
» Articles » PMID: 34973223

CONFIRM Trial: What is the Real Efficacy of Second-line Immunotherapy in Mesothelioma?

Overview
Journal Lancet Oncol
Specialty Oncology
Date 2022 Jan 1
PMID 34973223
Citations 5
Authors
Pierpaolo Correale
Francesca Pentimalli
Valerio Nardone
Antonio Giordano
Luciano Mutti
Affiliations
Soon will be listed here.
Citing Articles

A Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials.

Messori A, Trippoli S, Piragine E, Veneziano S, Calderone V Cancers (Basel). 2025; 17(3).

PMID: 39941870 PMC: 11815993. DOI: 10.3390/cancers17030503.

Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6.

Cioce M, Gatti V, Napolitano F, Giorgiano N, Marra A, Portella G Int J Mol Sci. 2024; 25(10).

PMID: 38791392 PMC: 11121414. DOI: 10.3390/ijms25105355.

Intratumor microbiota as a novel potential prognostic indicator in mesothelioma.

Pentimalli F, Krstic-Demonacos M, Costa C, Mutti L, Bakker E Front Immunol. 2023; 14:1129513.

PMID: 36999042 PMC: 10043377. DOI: 10.3389/fimmu.2023.1129513.

Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology.

Meirson T, Nardone V, Pentimalli F, Markel G, Bomze D, dApolito M J Transl Med. 2022; 20(1):593.

PMID: 36514092 PMC: 9749371. DOI: 10.1186/s12967-022-03744-6.

Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.

Kuryk L, Rodella G, Staniszewska M, Pancer K, Wieczorek M, Salmaso S Front Oncol. 2022; 12:916839.

PMID: 35785199 PMC: 9247278. DOI: 10.3389/fonc.2022.916839.